北京
分享至
泽璟制药(688266.SH)披露2026年半年度报告，报告期公司实现营收12.05亿元，同比增长220.88%;归属于上市公司股东的净利润6.4亿元，同比扭亏为盈;扣非净利润6.17亿元，同比扭亏为盈;基本每股收益2.42元。
本文源自：金融界AI电报
特别声明：以上内容(如有图片或视频亦包括在内)为自媒体平台“网易号”用户上传并发布，本平台仅提供信息存储服务。
Notice: The content above (including the pictures and videos if any) is uploaded and posted by a user of NetEase Hao, which is a social media platform and only provides information storage services.
